278 related articles for article (PubMed ID: 19579720)
1. Clinical and laboratory comparison of different brands of amphotericin B used for the treatment of Kala-azar: an observational study.
Narayan S; Gupta AK; Singh Subhankar K; Lal CS; Singh VP; Sinha PK; Das P; Thakur CP
J Commun Dis; 2008 Dec; 40(4):273-6. PubMed ID: 19579720
[TBL] [Abstract][Full Text] [Related]
2. [A case of antimony resistant kala-azar cured with amphotericin B].
Chen SB; Yang CM; Zhang CJ
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
[No Abstract] [Full Text] [Related]
3. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison.
Thakur CP; Sinha GP; Pandey AK; Barat D; Singh RK
Bull World Health Organ; 1994; 72(6):931-6. PubMed ID: 7867139
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B in resistant kala-azar in Bihar.
Thakur CP; Sinha GP; Pandey AK; Barat D; Sinha PK
Natl Med J India; 1993; 6(2):57-60. PubMed ID: 8477209
[TBL] [Abstract][Full Text] [Related]
5. Amphotericin B inhibits entry of Leishmania donovani into primary macrophages.
Paila YD; Saha B; Chattopadhyay A
Biochem Biophys Res Commun; 2010 Aug; 399(3):429-33. PubMed ID: 20678487
[TBL] [Abstract][Full Text] [Related]
6. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
7. Antileishmanial activity of nano-amphotericin B deoxycholate.
Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
[TBL] [Abstract][Full Text] [Related]
8. Leishmania donovani: an in vitro study of antimony-resistant amphotericin B-sensitive isolates.
Sharief AH; Gasim Khalil EA; Theander TG; Kharazmi A; Omer SA; Ibrahim ME
Exp Parasitol; 2006 Dec; 114(4):247-52. PubMed ID: 16716301
[TBL] [Abstract][Full Text] [Related]
9. The hunt for an elusive source of pyrexia in a foreign worker.
Lew JW; Koh CK; Selvan VS; Shen E
Singapore Med J; 2007 Apr; 48(4):e111-3. PubMed ID: 17384865
[TBL] [Abstract][Full Text] [Related]
10. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani.
Petit C; Yardley V; Gaboriau F; Bolard J; Croft SL
Antimicrob Agents Chemother; 1999 Feb; 43(2):390-2. PubMed ID: 9925541
[TBL] [Abstract][Full Text] [Related]
11. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
[TBL] [Abstract][Full Text] [Related]
12. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
13. Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.
Sinha PK; Ranjan A; Singh VP; Das VN; Pandey K; Kumar N; Verma N; Lal CS; Sur D; Manna B; Bhattacharya SK
J Infect; 2006 Jul; 53(1):60-4. PubMed ID: 16269185
[TBL] [Abstract][Full Text] [Related]
14. Kala-azar (visceral Leishmaniasis) from Khotang.
Joshi S; Bajracharya BL; Baral MR
Kathmandu Univ Med J (KUMJ); 2006; 4(2):232-4. PubMed ID: 18603904
[TBL] [Abstract][Full Text] [Related]
15. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
16. Study the effects of PLGA-PEG encapsulated amphotericin B nanoparticle drug delivery system against Leishmania donovani.
Kumar R; Sahoo GC; Pandey K; Das V; Das P
Drug Deliv; 2015 May; 22(3):383-8. PubMed ID: 24601828
[TBL] [Abstract][Full Text] [Related]
17. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
Murray HW
Int J Infect Dis; 2000; 4(3):158-77. PubMed ID: 11179920
[TBL] [Abstract][Full Text] [Related]
18. Detection of Leishmania infantum kinetoplast DNA in laryngeal tissue from an immunocompetent patient.
Guddo F; Gallo E; Cillari E; La Rocca AM; Moceo P; Leslie K; Colby T; Rizzo AG
Hum Pathol; 2005 Oct; 36(10):1140-2. PubMed ID: 16226116
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B in the treatment of visceral leishmaniasis.
Croft SL; Davidson RN; Thornton EA
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():111-8. PubMed ID: 1778888
[TBL] [Abstract][Full Text] [Related]
20. [Visceral leishmaniasis refractory to treatment: the efficacy of amphotericin B].
Pérez Brea A; Ruiz Moreno M; Leal Orozco A; Escorihuela Esteban R; Otero Fraguas M
An Esp Pediatr; 1996 Feb; 44(2):161-3. PubMed ID: 8830578
[No Abstract] [Full Text] [Related]
[Next] [New Search]
